PMID- 28241130
OWN - NLM
STAT- MEDLINE
DCOM- 20170426
LR  - 20210913
IS  - 1423-0224 (Electronic)
IS  - 0302-282X (Linking)
VI  - 74
IP  - 2
DP  - 2016
TI  - Nardostachys jatamansi Targets BDNF-TrkB to Alleviate Ketamine-Induced 
      Schizophrenia-Like Symptoms in Rats.
PG  - 104-114
LID - 10.1159/000454985 [doi]
AB  - OBJECTIVE: Schizophrenia, a common neurological disorder appearing in the late 
      teens or early adulthood, is characterized by disorganized thinking, behaviour, 
      and perception of emotions. Aberrant N-methyl-D-aspartate (NMDA) 
      receptor-mediated synaptic plasticity is a major pathological event here due to 
      dysfunction of dopamine and glutamate transmission at NMDA receptors. 
      De-regulated brain-derived neurotrophic factor (BDNF), i.e., its signalling 
      through the tropomyosin receptor kinase B (TrkB) receptor, is a major feature of 
      schizophrenia. With recent global awareness of traditional plant medicines in 
      reducing side effects, the aim of our study was to evaluate the efficacy of the 
      ethanolic root extract of a herb belonging to the Valerianacea family, 
      Nardostachys jatamansi, against ketamine-induced schizophrenia-like model in 
      rats. METHODS: The effect of the N. jatamansi drug (oral dosage of 500 mg/kg body 
      weight for 14 days) in ketamine-administered male Wistar albino rats (30 mg/kg 
      body weight for 5 days) on modulating behaviour and the level of 
      neurotransmitters like dopamine and glutamate was studied in whole-brain 
      homogenates, and its influence on BDNF and TrkB levels in 2 relevant brain 
      regions, the hippocampus and prefrontal cortex, was assessed. RESULTS: We 
      observed that N. jatamansi treatment exhibited encouraging results in the 
      modulation of ketamine-induced schizophrenia-like behaviours, principally the 
      positive symptoms. Our drug both significantly upregulated the glutamate level 
      and downregulated the dopamine level in whole-brain homogenates and retained the 
      normal levels of BDNF (in the hippocampus but not in the prefrontal cortex) and 
      TrkB (in both hippocampus and prefrontal cortex) induced by ketamine in rats. 
      CONCLUSION: These findings suggest a neuroprotective effect of the ethanolic root 
      extract of N. jatamansi against ketamine-induced schizophrenia-like symptoms in 
      rats; possibly, regarding its effect on TrkB signalling. Further research is 
      warranted in the treatment of schizophrenic symptoms.
CI  - (c) 2017 S. Karger AG, Basel.
FAU - Janardhanan, Anjali
AU  - Janardhanan A
AD  - Department of Biochemistry, University of Madras, Chennai, India.
FAU - Sadanand, Anjana
AU  - Sadanand A
FAU - Vanisree, Arambakkam Janardhanam
AU  - Vanisree AJ
LA  - eng
PT  - Journal Article
PT  - Retracted Publication
DEP - 20170228
PL  - Switzerland
TA  - Neuropsychobiology
JT  - Neuropsychobiology
JID - 7512895
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Plant Extracts)
RN  - 3KX376GY7L (Glutamic Acid)
RN  - 690G0D6V8H (Ketamine)
RN  - EC 2.7.10.1 (Receptor, trkB)
RN  - VTD58H1Z2X (Dopamine)
SB  - IM
RIN - Neuropsychobiology. 2022;81(1):83. PMID: 34517371
MH  - Animals
MH  - Behavior, Animal/drug effects
MH  - Brain/metabolism
MH  - Brain-Derived Neurotrophic Factor/*metabolism
MH  - Disease Models, Animal
MH  - Dopamine/metabolism
MH  - Glutamic Acid/metabolism
MH  - Ketamine
MH  - Male
MH  - Nardostachys/*chemistry
MH  - Phytotherapy/*methods
MH  - Plant Extracts/chemistry/*therapeutic use
MH  - Plant Roots/chemistry
MH  - Rats
MH  - Receptor, trkB/*metabolism
MH  - Schizophrenia/chemically induced/*drug therapy/*metabolism
EDAT- 2017/02/28 06:00
MHDA- 2017/04/27 06:00
CRDT- 2017/02/28 06:00
PHST- 2016/01/23 00:00 [received]
PHST- 2016/12/07 00:00 [accepted]
PHST- 2017/02/28 06:00 [pubmed]
PHST- 2017/04/27 06:00 [medline]
PHST- 2017/02/28 06:00 [entrez]
AID - 000454985 [pii]
AID - 10.1159/000454985 [doi]
PST - ppublish
SO  - Neuropsychobiology. 2016;74(2):104-114. doi: 10.1159/000454985. Epub 2017 Feb 28.